Colomycin (colistimethate sodium) is bactericidal against a range of gram-negative bacteria, including Pseudomonas aeruginosa, a key pathogen in CF. It has been demonstrated to be safe and effective; however, patients frequently report headaches and paraesthesia during therapy. We have recently demonstrated drug specific lymphocytes in patients with neurotoxicity suggesting an immune aetiology. In this study we measured specific IgE and IgG against Colomycin (Phadia, Uppsala, Sweden) in a cohort of patients at the Adult CF Unit in Leeds. In total 31 patients were tested, 17 had previous neurotoxicity (10 headaches, 7 paraesthesia), 7 had non-immediate urticarial skin reactions, and 7 were controls (4 tolerant, 3 naïve). The results are outlined in Table 1 . All specific IgE antibodies were negative. The colomycin specific IgG levels seen in the neurotoxicity group were significantly elevated compared to the control group (p = 0.006). 19 (0-16.8) This data further supports an immunological basis to neurological symptoms rather than the long held belief that it relates just to direct drug toxicity. We hypothesise that the headaches are the result of immune complex deposition due to binding of the specific IgG; perhaps by causing a low grade cerebral vasculitis. This phenomenon is seen usually in autoimmune disease but can rarely occur with drugs such allopurinol. Further work is needed to prospectively assess symptomatic patients during colomycin therapy.
